

Ivermectin tops metronidazole for papulopustular rosacea

7 April 2015



Two authors disclosed financial ties to Galderma R&D, which manufactures ivermectin and funded the study.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

(HealthDay)—For patients with papulopustular rosacea (PPR), once-daily ivermectin 1 percent cream (IVM 1 percent) is superior to twice-daily metronidazole (MTZ 0.75 percent) cream, according to a study published in the April issue of the *British Journal of Dermatology*.

Alain Taieb, M.D., Ph.D., from Hôpital Saint-André in Bordeaux, France, and colleagues conducted a phase 3 randomized trial involving patients with PPR. Participants were randomized to receive once-daily IVM 1 percent [cream](#) (478 [participants](#)) or twice-daily MTZ 0.75 percent cream (484 participants) for 16 weeks. Inflammatory lesion counts and Investigator's Global Assessment (IGA) were used to assess efficacy.

The researchers found that IVM 1 percent was significantly superior to MTZ 0.75 percent at week 16 in terms of reduction in [inflammatory lesions](#) from baseline (83.0 versus 73.7 percent; P

"In conclusion, while MTZ 0.75 percent cream has been the standard treatment for the papulopustular lesions of rosacea, its efficacy is now surpassed by that of IVM along with the advantage of once-daily dosing and high patient satisfaction," the authors write.

APA citation: Ivermectin tops metronidazole for papulopustular rosacea (2015, April 7) retrieved 11 October 2022 from <https://medicalxpress.com/news/2015-04-ivermectin-tops-metronidazole-papulopustular-rosacea.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.